ClinicalTrials.gg
Not yet recruitingNCT07167498Updated Apr 8, 2026

Continuous Remote Vital Sign Monitoring During Labour Analgesia With Remifentanil

An observational study in Labor Pain, sponsored by Nordsjaellands Hospital. Not yet recruiting at 1 site in Denmark. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Nordsjaellands Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Continuous remote vital sign monitoring during labour analgesia with remifentanil - a prospective observational study

Remifentanil PCA represents a well-tolerated, effective and valuable option for labour analgesia, yet its wider implementation is still limited by concerns of opioid side-effects particularly the risk of respiratory depression leading to desaturation, potentially affecting the foetus. Thus, continuous one-to-one observation and monitoring in the delivery room, with the midwife unable to leave the patient unattended, is recommended. Such constant one-to-one monitoring may be challenging in present health-care settings where staffing constraints may limit the implementation of remifentanil as routine obstetric care.

Continuous remote vital sign monitoring to display oxygen saturation (SpO₂), respiratory rate, and heart rate on a handheld device (smartphone), has the potential to address this barrier by allowing the midwife to leave the labour room for short, predefined intervals while maintaining continuous surveillance of maternal vital signs. Such an approach could free staff resources without compromising patient safety. While centralised foetal monitoring (CTG) is standard practice in many units, the application of continuous remote vital sign monitoring for women receiving remifentanil during labour has, to our knowledge, never been formally studied.

Objectives The aim is to study whether remote monitoring during remifentanil patient-controlled analgesia (PCA) for labour affects the incidence of maternal desaturation and other safety outcomes (bradypnoea, bradycardia, and neonatal outcomes, assessed via Apgar scores and umbilical cord pH.) The study will be conducted in a setting where remifentanil PCA is administered for labour analgesia and the midwife is permitted to leave the labour room for intervals of up to 10 minutes while the woman is remotely monitored using a handheld device carried by the midwife. Predefined criteria for when the woman must be accompanied (e.g., if SpO₂ \< 94%, supplemental oxygen >2L/min., or decreased consciousness). Outcomes in this group will be compared with a control group where the midwife remains continuously present in the labour room.

Read the detailed description

Introduction Remifentanil, a potent, ultra-short-acting opioid, administered intravenously via patient-controlled analgesia (PCA) has been used for more than a decade in several countries, particularly in Switzerland and at the Ulster Hospital in Ireland. In 2024, remifentanil was formally included as a standard option for labour analgesia in the United Kingdom and incorporated into the guidelines from the National Institute for Health and Care Excellence (NICE). The REMIPCA SAFE Network collaboration has further demonstrated that remifentanil PCA is a safe and effective method for labour analgesia, offering rapid onset, patient autonomy, and high maternal satisfaction (remiPCA.org).

In many European and Anglophone countries, nitrous oxide and epidural analgesia remain the most commonly used pharmacological methods for labour analgesia, while the use of remifentanil is not yet widespread in all settings. Nitrous oxide cause nausea and is under increasing scrutiny due to environmental concerns, while epidural analgesia, although highly effective for pain relief, is more invasive, resource intensive and associated with rare but severe complications.

Remifentanil PCA represents a well-tolerated, effective and valuable option for labour analgesia, yet its wider implementation is still limited by concerns of opioid side-effects particularly the risk of respiratory depression leading to desaturation, potentially affecting the foetus. Thus, continuous one-to-one observation and monitoring in the delivery room, with the midwife unable to leave the patient unattended, is recommended. Such constant one-to-one monitoring may be challenging in present health-care settings where staffing constraints may limit the implementation of remifentanil as routine obstetric care.

Continuous remote vital sign monitoring to display oxygen saturation (SpO₂), respiratory rate, and heart rate on a handheld device (smartphone), has the potential to address this barrier by allowing the midwife to leave the labour room for short, predefined intervals while maintaining continuous surveillance of maternal vital signs. Such an approach could free staff resources without compromising patient safety. While centralised foetal monitoring (CTG) is standard practice in many units, the application of continuous remote vital sign monitoring for women receiving remifentanil during labour has, to our knowledge, never been formally studied.

Objectives The aim is to study whether remote monitoring during remifentanil for labour analgesia affects the incidence of maternal desaturation and other safety outcomes (bradypnoea, bradycardia, and neonatal outcomes, assessed via Apgar scores and umbilical cord pH.) This will be assessed in a setup where remifentanil PCA for labour analgesia is given and the midwife is allowed maximum absence intervals of 10 minutes with predefined criteria for when the woman must be accompanied (e.g., if SpO₂ \< 94%, supplemental oxygen >2L/min., or decreased consciousness) and compared with a control group where the midwife is in the labour room continuously.

Methods

Ethics The study will be conducted in compliance with the Declaration of Helsinki. Participation will be voluntary, and written informed consent will be obtained prior to inclusion. Participants may withdraw their consent at any time without consequences for their further treatment. Approval for data collection, processing, and storage will be sought from the Data Protection Authority for the Capital Region of Denmark prior to study initiation. The National committee on health research ethics, Denmark has approved the study in accordance with Danish legislation (ID: 2203648, date: 2024-06-25). All collected data will be handled in strict confidence and anonymised prior to analysis. The study protocol will be registered at ClinicalTrials.gov before inclusion of the first patient.

Study design A single centre before and after prospective observational study. Based on maternal and neonatal physiological parameters in parturients giving birth with remifentanil PCA for labour analgesia, using continuous remote vital sign monitoring, while the attending midwife is either continuously present in the labour room (group 1) or intermittently present, with absence intervals of up to 10 minutes (group 2)

Setting Location The study will be conducted at the labour ward of North Zealand Hospital. Recruitment period Recruitment is expected to be completed between 1 October 2025 and 31 December 2026.

Data collection Continuous monitoring of oxygen saturation (SpO₂), cardiotocography (CTG), respiratory rate, and heart rate during labour will be registered for analysis. Oxygen saturation (SpO₂), respiratory rate, and heart rate will be collected using the WARD technology (WARD247 Aps, Copenhagen, Denmark) and consists of threadless body-sensors which monitor oxygen saturation (SpO₂), ECG and respiratory rate every minute. These data are then electronically transferred to the WARD monitoring application on a handheld mobile device (smartphone). The adhesive body sensors are applied using a bracelet for the wrist and two ECG electrodes on the chest allowing considerable freedom of movement. CTG will be collected with Umbilical cord pH will be measured in all participants. Additional maternal and neonatal physiological parameters will be obtained from health records from the birth admission. The midwife will register when they are absent from the labour room, including frequency and duration of absences.

Remifentanil administration for labour analgesia Remifentanil is administered as patient-controlled analgesia (PCA) via an intravenous line. When the parturient presses the PCA button, a bolus of 20 µg remifentanil (corresponding to 1 mL) is delivered; the bolus dose may be adjusted between 10 µg and 30 µg. The lockout interval is 2 minutes. Administration must be discontinued around 10 minutes prior to delivery. The parturient is monitored for oxygen saturation (SpO₂), respiratory rate, cardiotocography (CTG), and heart rate. Each parturient will receive one-to-one midwifery care, as is standard practice in Denmark. The use of labour analgesia will be adapted to the individual course of labour, and medical pain management during active labour may include nitrous oxide, remifentanil, and epidural analgesia.

In the department's standard operating procedure, adapted from remipca.org, the target oxygen saturation (SpO₂) during the use of remifentanil is > 93%. If SpO₂ is \< 94% for more than two minutes supplemental oxygen should be administered, either via face mask for short desaturation episodes or via nasal cannula.

When the parturients are receiving remifentanil for labour analgesia in the study protokol:

Group 1: The midwife stays in the labour room Group 2: the midwife is permitted to leave the labour room for intervals of up to 10 minutes while carrying a personal handheld device that displays continuous SpO₂, respiratory rate, and heart rate for remote monitoring. The monitoring system presents SpO₂, HR and RR continuously on the screen (updated every minute), and the midwife is responsible for continuous observation via the remote monitoring system and must respond immediately if SpO₂ falls below 94% or RR are below 10. As a safety precaution, an alarm is triggered after 10 minutes if SpO2 falls below 88%, after 5 minutes if SpO₂ falls below 85%, and immediately if SpO₂ falls below 80% and immediately if RR falls to ≤5 brpm.

The midwife is only permitted to leave the labour room if the parturient receiving remifentanil is awake, responsive, and accompanied by a partner who is capable and instructed to call for assistance if SpO₂ drops below 94% or if the parturient becomes unconscious. CTG will be centrally monitored at the ward level by the ward responsible midwife, who maintains an overview of CTG tracings from all delivery rooms.

As an extra safety precaution during this study, the ward-responsible midwife will also be informed if the attending midwife leaves the room and will be able to monitor the SpO₂ together with the CTG via the central monitoring system connected to all delivery rooms.

02

Conditions studied

  • Labor Pain

Browse trials for

Keywords

  • remifentanil
  • labour analgesia
  • remote monitoring
  • safety
03

In context

Labor Pain

426 studies on the registry are indexed under Labor Pain; 76 are open to participants now.

This study's planned enrollment of 80 is below the median of 140 across 63 observational studies indexed under Labor Pain.

Browse Labor Pain studies →

Lead sponsor

Nordsjaellands Hospital is the lead sponsor of 89 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study will be conducted at the labour ward of North Zealand Hospital. All parturients who meet the eligibility criteria may be included, provided that qualified staff are available at the time of admission.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum 18 years of age
  • Able to provide written
  • Giving birth to a singleton, cephalic presenting, expected healthy child, gestational age > 37 weeks.
  • In active labour

Exclusion criteria

Exclusion criteria

  • Respiratory or cardiac disease
  • ≥ 40 Other opioids within the last 4 hours.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: The midwife stays in the labour room during remifentanil PCA for labour analgesia

    Group 1: The midwife stays in the labour room while the parturient are having remifentanil for labour analgesia.

    Behavioral: Intermittent midwife absence during remote monitoring of remifentanil PCA in labour

  • Group 2: The midwife can leave the labour room during remifentanil PCA for labour analgesia

    Group 2: the midwife is permitted to leave the labour room for intervals of up to 10 minutes while carrying a personal handheld device that displays continuous SpO₂, respiratory rate, and heart rate for remote monitoring.

    Behavioral: Intermittent midwife absence during remote monitoring of remifentanil PCA in labour

Interventions

  • BehavioralIntermittent midwife absence during remote monitoring of remifentanil PCA in labour

    Midwife absence during remifentanil PCA for labour analgesia. We aim to include a total of 80 participants. All will receive remifentanil PCA for labour analgesia and be monitored with remote monitoring equipment. First a group of 40 parturients will be included, and the attending midwife will not be allowed to leave the parturient (Group 1). A following group of 40 parturients will then be included and the attending midwife can leave the room in intervals up to 10 minutes (Group 2).

06

What researchers measure

Primary outcomes

  1. Incidence of SpO₂ 90-93% lasting more than 2 minutes

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

Secondary outcomes

  1. Incidence of SpO2 89-85% lasting more than one minute

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

  2. Any incidence of SpO2 < 85%

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

  3. Incidence of RR < 9 for ≥5 minutes

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

  4. Incidence of neonates with Apgar score < 7

    During the use of remifentanil for labour analgesia.

    Time frame: measured 5 minutes after birth

Other outcomes

  1. Incidence of parturient being unconscious assessed by AVPU assessment scale (Alert, Voice, Pain, Unresponsive) during the use of remifentanil for labour analgesia.

    During the use of remifentanil for labour analgesia.

    Time frame: During the use of remifentanil for labour analgesia.

  2. Incidence of HR < 50

    During the use of remifentanil for labour analgesia.

    Time frame: During the use of remifentanil for labour analgesia.

  3. Incidence of RR ≤5

    During the use of remifentanil for labour analgesia.

    Time frame: During the use of remifentanil for labour analgesia.

  4. Incidence of neonates with umbilical cord pH < 7.00

    During the use of remifentanil for labour analgesia.

    Time frame: measured within minutes after birth

  5. Cumulative duration of SpO2 <85% per patient

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

  6. Cumulative duration SpO2 89-85% per patient

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

  7. Cumulative duration of SpO2 90-94% per patient

    During the use of remifentanil for labour analgesia.

    Time frame: During labour

07

Study locations

1 site
  • University Hospital of Copenhagen, Northern Zealand
    Hillerød, 3400, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 31 non-industry observational studies under Labor Pain, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 13 months is above that.

Counting every sponsor, half of 32 studies reached it within 9 months; a quarter within 6 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 11, 2025
StartEst.
Nov 1, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07167498
Lead sponsor
Nordsjaellands Hospital
Responsible party
Patricia Duch (Consultant, MD, Nordsjaellands Hospital) — Principal investigator
First posted
Sep 11, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

Patricia Duch, MD
Contact
Patricia.duch@regionh.dk
+45 48292504
Laura Fugmann, Cand. Soc
Contact
Laura.Fugmann@regionh.dk
Patricia Duch, MD
principal investigator · Nordsjaellands Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion